Glenda buys ENDP 71.06: One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock.

ENDP has been the subject of a number of other reports. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D arrangement with the Firm. The Business has a portfolio of branded pharmaceuticals that contains brands, for example Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. Endo International PLC, previously Endo Health Solutions Inc. is a specialty healthcare solutions business focused on branded and generic pharmaceuticals, devices and services. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company.


Kassie:
The 200-day and 50-day moving averages have moved 0.08% higher and 1.27% lower over the past week, respectively.

Arlean:
In June 2014, intellectual property developed within the framework of an R&D arrangement with the Firm. was obtained by Trendlines Group In July 2014, it got Grupo Farmaceutico Somar.

Tyisha:
The Firm has a portfolio of branded pharmaceuticals that contains brands, such as Voltaren Gel, Opana ER, Lidoderm, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Helaine:
One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock.

Renae:
Federal Trade Commission in connection with Endo's previously announced acquisition of Par Pharmaceutical Holdings, Inc.

Mabelle:
Now you can see it all for free.

Keesha:
Endo expressly disclaims any intent or obligation to update forward-looking statements except as required by law.

Karry:
Accordingly, you should not place undue reliance on any forward-looking statements, which apply only as of the date of this press release.

Sally:
If underlying assumptions prove inaccurate, or unknown risks or uncertainties materialize, results could vary from Endo's expectations.

Jan:
As a result, all closing conditions relating to the Par acquisition have been satisfied and the parties will promptly proceed with the closing pursuant to the terms of the merger agreement.

Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP)
//stockhand.net/us/?q=nasdaq%3Aendp&id=680177